Edition:
United States

Evogene Ltd (EVGN.OQ)

EVGN.OQ on NASDAQ Stock Exchange Global Market

3.51USD
3:59pm EST
Change (% chg)

$-0.18 (-4.88%)
Prev Close
$3.69
Open
$3.51
Day's High
$3.51
Day's Low
$3.46
Volume
1,275
Avg. Vol
2,118
52-wk High
$5.76
52-wk Low
$3.46

Summary

Name Age Since Current Position

Martin Gerstel

73 2004 Chairman of the Board

Ofer Haviv

47 2004 President, Chief Executive Officer

Alex Taskar

2017 Chief Financial Officer

Yuval Ben-Galim

2016 Chief Operating Officer

Hagai Karchi

53 2004 Executive Vice President, Chief Technology Officer

Amos Shachar

39 2012 Vice President of Project Management

Lea Slonim Bloom

43 2010 Director of Administration & Human Resources

Sarit Firon

2016 Director

Adina Makover

65 2003 Director

Leon Recanati

67 2005 Director

Simcha Sadan

73 2006 Director

Eli Zangvil

46 2006 Director

Michael Anghel

78 2007 External Director

Kinneret Livnath Savitzky

46 2010 External Director

Biographies

Name Description

Martin Gerstel

Mr. Martin Gerstl serves as Chairman of the Board at Evogene Ltd. since 2004. He serves as Chairman of Compugen Ltd., a drug and diagnostic discovery company, of Keddem Bioscience, a drug discovery company and he also serves as Co-Chairman of Itamar Medical, a medical device company, all of which are headquartered in Israel. Prior to relocating to Israel in 1994, Mr. Gerstel was the Co-Chairman and CEO of ALZA Corporation, a pharmaceutical company based on advanced drug delivery. In addition, Mr. Gerstel currently serves as a Director of YEDA Technology Transfer, Yissum Technologies and the Foundation for the US National Medals of Science and Technology. He is a member of the Board of Governors and the Executive Committee of the Weizmann Institute of Science and the Board of Governors of the Hebrew University of Jerusalem, and is an advisor to the Burrill Life Science Funds and to the Board of the Israel-U.S. BiNational Industrial Research and Development (BIRD) Foundation. Mr. Gerstel holds a BSC degree in Science from the Yale University and an MBA degree from the Stanford University.

Ofer Haviv

Mr. Ofer Haviv serves as Chief Executive Officer and President of Evogene Ltd. since December, 2004. Mr. Haviv held the positions of Company COO and CFO from 2002 to 2004 and was involved in Evogene's spin-off from Compugen Ltd. Prior to the spin-off, he held the position of Director of Finance and Treasurer of Compugen Ltd. for four years, during which time the company completed two private placements and an IPO on NASDAQ. Earlier, Mr. Haviv was the CFO of Klei Zemmer. He was also an auditor with an accounting firm belonging to a network of the Big Five. Mr. Ofer Haviv holds a BA degree in Economics from the Tel Aviv University and is also a Certified Public Accountant in Israel.

Alex Taskar

Mr. Alex Taskar has been appointed interim Chief Financial Officer at Evogene Ltd effective January 1, 2017.

Yuval Ben-Galim

Mr. Yuval Ben-Galim has been appointed Chief Operating Officer at Evogene Ltd. effective September 15, 2016. His work experience includes the following roles: Chief Product Development at Como, Chief Operating Officer at MyHeritage (2011-2015), He holds a Bachelor of Science degree in Computer Science and Business Administration and a Master of Science degree in Computer Science, both from The Hebrew University of Jerusalem.

Hagai Karchi

Dr. Hagai Karchi serves asExecutive Vice President and Chief Technology Officer at Evogene Ltd. since 2004. He is co-founder of Evogene Ltd. He served as the Company's CEO from 2002 until 2004. Prior to the spin-off of Evogene Ltd. from Compugen Ltd. he was the Co-Head of Compugen's Plant Genomic Division. He has over 15 years experience in the breeding of tomatoes and in molecular genomics research. His scientific achievements include the development of a molecular system for gene discovery and the development of high yielding, high quality greenhouse tomato varieties. Dr. Karchi has lectured widely in the field of plant genomics and has several publications. Dr. Karchi holds B.Sc and M.Sc degrees in Genetics from the Hebrew University of Jerusalem’s Faculty of Agriculture, specializing in gene expression. He also holds a joint Ph.D. degree in Genetics from The Weizmann Institute of Science, Israel.

Amos Shachar

Lea Slonim Bloom

Ms. Lea Slonim Bloom serves as Director of Administration & Human Resources at Evogene Ltd since September 19, 2010. Prior to her appointment, Ms. Slonim Bloom served as the Company's Director of Operations & Human Resources from 2009 to September 19, 2010. Ms. Slonim Bloom has a Bachelors degree in Occupational Therapy and a Master of Science degree in Occupational Therapy, both from the Tel Aviv University.

Sarit Firon

Ms. Sarit Firon has been appointed Director at Evogene Ltd effective August 11, 2016. Ms. Sarit Firon is a finance executive. Her work experience includes the following roles: Director at MediWound, Datorama and Chairperson of myThings. She has nearly two decades of experience as Chief Financial Officer at numerous hi-tech companies. Ms. Firon holds a Bachelors degree in Accounting and Economics from Tel Aviv University.

Adina Makover

Dr. Adina Makover serves as Director at Evogene Ltd. since 2003. She currently serves as Director of Life Sciences Investments at Proseed VC and is a consultant to private investors. For the past four years, Dr. Makover has been the Managing Director of Tzina Bio Perspective. Previously, she held senior management positions in biotech and device companies focusing on drugs, diagnostics and tissue engineering. Holding positions of CEO and board member, research and development, process development and production manager, Dr. Makover was responsible for both the technology and business aspects. Dr. Makover holds a joint PhD degree in Life Sciences from Columbia University (USA) and Weizmann Institute of Science (Israel) and performed post-doctoral research at the Weizmann Institute of Science. Dr. Makover also holds an MBA degree from the Bar-Ilan University.

Leon Recanati

Mr. Leon Recanati serves as Director at Evogene Ltd. since 2005. He is the founder and CEO of GlenRock Israel, a private equity group. Mr. Recanati was Chairman and CEO of IDB Holding Corporation until May 2003. In addition, he served as Chairman of Clal Industries and Investments, Discount Investment Corporation, and Azorim Investment Development and Construction. Mr. Recanati was Chairman of Delek Israel Fuel Corporation and Super-Sol until 1997, in addition to several other positions in a variety of operating companies in Israel. Mr. Recanati serves as Chairman of the Board of the Israel National Museum of Science in Haifa, Vice Chairman of the Israel Cancer Association and Chairman of Tel-Aviv University's Development Committee. He is also an active member of the Board of Governors of Tel-Aviv University and the Hebrew University of Jerusalem, The Technion Israel Institute of Technology, The Jewish Agency, and Chairman of Tapuah - The Israeli Society for the Advancement of the Information Age. Mr. Recanati received his BA in Economics and MBA degree, both from The Hebrew University of Jerusalem and Honorary Doctorates from the Technion Israel Institute of Technology and Tel-Aviv University.

Simcha Sadan

Dr. Simcha Sadan serves as Director at Evogene Ltd. since 2006. He had served as a member of the board of directors of Rosetta Genomics Limited from December 2006 until October 2009. Dr. Sadan has been serving as the Chairman of the Board of Club Hotel Europe Ltd. and of Premier Club Ltd. He also served as an Alternate Director at several public companies, such as, Shaniv Household Paper Industry Limited, Haribua Hakachol, Telkoor Telecom Ltd. and others. Dr. Sadan also held different executive and consultancy positions and was also a member of governmental and professional committees. Dr. Sadan had been a member of the Faculty of Management at Tel Aviv University. Dr. Sadan holds a Ph.D. in Business Administration from the University of California, Berkeley, an MBA majoring in Finance and Accounting, a BA in Economics and Statistics from the Hebrew University of Jerusalem and an LLB from the Faculty of Law at the Tel-Aviv University.

Eli Zangvil

Dr. Eli Zangvil served as Director at Evogene Ltd. from 2006 until 2011. He currently serves as Vice President, Business Development at Compugen. Prior to this, he served as Chief Operating Officer of UltraShape. Previously, Dr. Zangvil was Head of Medical Services of the Israeli Defense Force's Central Command, where he held the rank of Colonel. Prior to this, he held the position of Assistant Director of the Rambam Medical Center in Haifa, Israel. Dr. Zangvil holds a Doctorate of Medicine degree in Medical Sciences from the Hebrew University of Jerusalem, and specializes in internal medicine. He also has a Masters Degree in Health Administration from the Tel-Aviv University, Israel.

Michael Anghel

Dr. Michael J. Anghel serves as External Director at Evogene Ltd. since 2007. He serves as a member of various boards of Israeli corporations, including Partner Ltd., Syneron Medical Ltd., ECI Telecom Ltd. and Scopus Ltd. Previously, Dr. Anghel served on the management board of the Discount Investment Corporation and as CEO of Discount Capital Markets, the investment banking arm of the Israel Discount Bank. He was actively involved in the founding and management of various technology and communications enterprises including Cellcom and Tevel. Dr. Anghel holds a BA in Economics (1960) from the Hebrew University of Jerusalem and an MBA (1964) and Ph.D. (1969) in International Finance from the Columbia University in New York.

Kinneret Livnath Savitzky

Dr. Kinneret Livnath Savitzky serves as External Director at Evogene Ltd since September 17, 2010. Dr. Livnath Savitzky has a Bachelors degree in Biochemistry from the Tel Aviv University, a Bachelors degree in Biology from The Hebrew University of Jerusalem and a Doctorate in Philosophy degree in Molecular Biology from the Tel Aviv University.